1. Show article details.

    Moderna rally loses steam over COVID-19 vaccine worries

    Reuters – 3:48 PM ET 05/27/2020

    - Shares of biotechs racing to make coronavirus vaccines, including Moderna Inc (MRNA) , fell about 10% on Wednesday, as investor concerns grew about the prospects of the experimental products that are still in early stages of development.

  2. Show article details.

    INOVIO to Host Webinar "DNA Medicines: From COVID-19 to Cancer"

    PR Newswire – 8:00 AM ET 05/26/2020

    PLYMOUTH MEETING, Pa., May 26, 2020  INOVIO, a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases, cancer, and diseases associated with HPV, today announced it will hold a webinar event on June 1 from 10 AM to noon EDT to detail its proprietary DNA medicines technology and provide updates on INO-4800,...

  3. Show article details.

    Sinovac says it has started mid-stage human trials of COVID-19 vaccine

    Reuters – 10:55 AM ET 05/22/2020

    Sinovac Biotech Ltd (SVA) said on Friday it had started mid-stage human trials of its experimental coronavirus vaccine in China earlier this month. The China-based company said it has received $15 million in funding from two investors that will help speed up development of the vaccine, dubbed CoronaVac.

  4. Show article details.

    Human trials of British coronavirus vaccine to reach 10,000

    Reuters – 7:49 AM ET 05/22/2020

    * Front-line workers sought, children and elderly added. * Trial results may take 2-6 months to come through. * AstraZeneca (AZN) has backing for manufacturing from UK, U.S. By Ludwig Burger. Oxford University and AstraZeneca (AZN) are recruiting around 10,000 adults and children in Britain for trials of an experimental coronavirus vaccine, a day after receiving U.S. backing worth up to $1.2 billion.

  5. Inovio Pharmaceuticals started at buy with $28 stock price target at Benchmark

    MarketWatch – 7:20 AM ET 05/21/2020
  6. Show article details.

    US STOCKS-Wall St set to rise as investors hold out for recovery

    Reuters – 8:40 AM ET 05/20/2020

    * Lowe's (LOW) up after results. * U.S. indexes seen in tight range in near term - economist. * Futures up: Dow 1.15%, S&P 1.10%, Nasdaq 1.00% By Medha Singh and Ambar Warrick.

  7. Show article details.

    Inovio's stock gains on early data testing its COVID-19 vaccine in animals

    MarketWatch – 7:31 AM ET 05/20/2020

    Shares of Inovio gained 22.8% in premarket trading on Wednesday after the company said its COVID-19 vaccine candidate demonstrated neutralizing antibodies in animals. The data, published in Nature Communications, is from a preclinical study, meaning it does not include information about how the investigational vaccine reacts in humans but in mice and guinea pigs. Inovio is currently conducting a Phase 1 clinical trial testing the DNA vaccine candidate in people; early data...

  8. Show article details.

    Inovio says COVID-19 vaccine produces antibodies in mice, guinea pigs

    Reuters – 7:00 AM ET 05/20/2020

    U.S. immunotherapy company Inovio Pharmaceuticals Inc (INO) on Wednesday said its experimental vaccine to prevent coronavirus infection was shown to produce protective antibodies and immune system responses in mice and guinea pigs.

  9. Show article details.

    INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models

    PR Newswire – 7:00 AM ET 05/20/2020

    PLYMOUTH MEETING, Pa., May 20, 2020  INOVIO today announced the publication of the preclinical study data for IN0-4800, its COVID-19 DNA vaccine, demonstrating robust neutralizing antibody and T cell immune responses against coronavirus SARS-CoV-2.

  10. Show article details.

    These 23 companies are working on coronavirus treatments or vaccines -- here's where things stand

    MarketWatch – 12:02 PM ET 05/16/2020

    The list includes Gilead Sciences (GILD) and Moderna (MRNA), alongside smaller biotech companies. A mix of legacy drug makers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel coronavirus. COVID-19, which was first detected in December in Wuhan, China, has since sickened nearly 4.6 million people worldwide and killed more than 300,000, as of mid-May.

  11. Show article details.

    Correction to Coronavirus Cure Investing Article

    DJ Business News – 10:21 PM ET 05/14/2020

    Moderna Inc. (MRNA) is currently moving through human trials for its Covid-19 vaccine. "Why Big Investors Aren't Betting It All on a Coronavirus Cure," at 2:35 p.m. ET and updates at 4:20 p.m. and 5:44 p.m., incorrectly said it is moving closer to human trials. (END) Dow Jones Newswires 05-14-20 2221 ET Copyright (c) 2020 Dow Jones& Company, Inc..

  12. Show article details.

    Why Big Investors Aren't Betting It All on a Coronavirus Cure

    DJ Business News – 2:50 PM ET 05/14/2020

    As drug companies race to discover treatments for the new coronavirus, big investment firms are placing cautious bets on likely winners. Hedge funds and venture-capital firms, who are in the business of predicting the future for companies and economies, are growing more confident researchers will develop effective drugs to fight the pandemic. Yet, successful efforts that could help millions-- or even billions-- of people, might not result in big profits for shareholders, the...

  13. Show article details.

    BRIEF-Inovio Says 85% Of Glioblastoma Patients Treated With INO-5401 Combined with Libtayo Alive for at least 12 Months

    Reuters – 7:25 AM ET 05/14/2020

    Inovio Pharmaceuticals Inc (INO): * INOVIO'S INO-5401 IN COMBINATION WITH PD-1 INHIBITOR LIBTAYO® DEMONSTRATES 85% OF NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS ARE ALIVE 12 MONTHS FOLLOWING TREATMENT Source text for Eikon: Further company coverage:

  14. Show article details.

    INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment

    PR Newswire – 7:00 AM ET 05/14/2020

    PLYMOUTH MEETING, Pa., May 14, 2020 INOVIO today announced that 85 percent of patients newly diagnosed with the deadly brain cancer glioblastoma multiforme who received the company's DNA medicine INO-5401, in combination with INO-9012 and PD-1 inhibitor Libtayo®, were alive for at least 12 months or more following treatment. GBM is the most common and aggressive type of brain cancer.

  15. Show article details.

    The Evolving Medical Field Turns to Remote Patient Monitoring Devices

    PR Newswire – 9:00 AM ET 05/13/2020

    NEW YORK, May 13, 2020   The role medical devices play in our healthcare system has suddenly changed. Additionally, there have been some impressive innovations across various fields of medicine during the pandemic, including potential vaccines, personal protective equipment and monitoring devices.

  16. Show article details.

    BRIEF-Inovio Pharmaceuticals Says It Files Prospectus Supplement Related To $100 Million Common Stock Offering

    Reuters – 5:04 PM ET 05/12/2020

    Inovio Pharmaceuticals Inc (INO): * INOVIO PHARMACEUTICALS SAYS IT FILES PROSPECTUS SUPPLEMENT RELATED TO $100 MILLION COMMON STOCK OFFERING - SEC FILING Source text: Further company coverage:

  17. Show article details.

    INOVIO to Present at RBC Capital Markets Virtual Global Healthcare Conference

    PR Newswire – 8:00 AM ET 05/12/2020

    PLYMOUTH MEETING, Pa., May 12, 2020 INOVIO today announced that Dr. J. Joseph Kim, President and CEO, along with other members of management will present in a fireside discussion at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2020 at 2:30 p.m. Eastern Time.

  18. Show article details.

    Barbuto & Johansson, P.A. Reminds Investors of Today’s Deadline in the Inovio Pharmaceuticals Class Action and Encourages Shareholders with Losses Exceeding $100,000 to Contact the Firm

    GlobeNewswire – 2:05 AM ET 05/12/2020

    Barbuto & Johansson, P.A. reminds investors that today is the last day to contact the Firm to learn more about the class action filed against Inovio Pharmaceuticals, Inc. (INO), and appointment of lead plaintiff.

  19. Show article details.

    INOVIO 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Inovio Pharmaceuticals - INO

    PR Newswire – 10:50 PM ET 05/11/2020

    NEW ORLEANS, May 11, 2020  Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until May 12, 2020 to file lead plaintiff applications in a securities class action lawsuit against Inovio Pharmaceuticals (INO), if they purchased the Company's shares between February 14, 2020 and March 9, 2020, both dates inclusive.

  20. Show article details.

    Epidemic response group to invest up to $384 mln in Novavax's COVID-19 vaccine

    Reuters – 5:03 PM ET 05/11/2020

    The Coalition for Epidemic Preparedness Innovations will invest up to $384 million to help develop and produce Novavax Inc's COVID-19 vaccine candidate, the company said on Monday, sending its shares up 31.2% in extended trading.

Page:

Today's and Upcoming Events

  • Aug
    10

    INO to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    11

    INO announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.